Birinapant, demcizumab, etirinotecan pegol, mafodotin, pexastimogene devacirepvec, rabusertib, rimilogene galvacirepvec, vintafolide, vorsetuzumab

Recently adopted names for antitumoral compounds (April 2012) - Noms d’antitumoraux adoptés récemment (avril 2012)

Birinapant, demcizumab, etirinotecan pegol, mafodotin, pexastimogene devacirepvec, rabusertib, rimilogene galvacirepvec, vintafolide, vorsetuzumab

Name (nom)	Code name	Type	Target(s)
birinapant	TL32711	Synthetic small peptidomimetic molecule	Smac ( Second mitochondrial-derived activator of caspases)
demcizumab	OMP-21M18	Monoclonal antibody	Delta-like 4 ligand (DLL4), an activator of Notch signaling
etirinotecan pegol	NKTR-102	Irinotecan conjugate (natural product-derived small molecule)	Topoisomerase I
mafodotin	mc-MMAF, mcMMAF, SGD-1269, monomethyl auristatin F	Peptide	Tubulin
pexastimogene devacirepvec	JX-594, TG6006	Thymidine kinase-deleted oncolytic poxvirus	Cancer cells
rabusertib	LY2603618, IC-83	Small inhibitory molecule	Cell cycle checkpoint kinase  (chk)
rimilogene galvacirepvec	Prostvac-V	Recombinant vaccinia virus vaccine	Prostate-specific antigen (PSA)
vintafolide	EC145	Vinca alkaloid conjugate	Microtubules
vorsetuzumab	SGN-70	Monoclonal antibody	CD70